Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study

Objectives Palonosetron is a novel 5-hydroxytryptamine 3 (5 HT 3 ) receptor antagonist, which has been shown to be superior to first generation 5 HT 3 receptor antagonists regarding the prevention of acute, delayed and overall chemotherapy-induced nausea and vomiting. First generation 5 HT 3 recepto...

Full description

Saved in:

Bibliographic Details
Published in:	Supportive care in cancer Vol. 20; no. 10; pp. 2343 - 2347
Main Authors:	Yavas, C., Dogan, U., Yavas, G., Araz, M., Ata, O. Yavas
Format:	Journal Article
Language:	English
Published:	Berlin/Heidelberg Springer-Verlag 01-10-2012 Springer Springer Nature B.V
Subjects:	Adolescent Adult Aged Antineoplastic Agents - adverse effects Cancer Cancer patients Cancer therapies Cardiac patients Care and treatment Chemotherapy Electrocardiogram Electrocardiography Electrocardiography - drug effects Heart Heart beat Heart Rate - drug effects Humans Isoquinolines - pharmacology Medicine Medicine & Public Health Middle Aged Nausea Nausea - chemically induced Nausea - prevention & control Neoplasms - drug therapy Nursing Nursing Research Oncology Oncology, Experimental Original Article Pain Medicine Preventive medicine Prospective Studies Quinuclidines - pharmacology Rehabilitation Medicine Serotonin Antagonists - pharmacology Vomiting Vomiting - chemically induced Vomiting - prevention & control Young Adult Cardiac effect receptor antagonist Eectrocardiography 5 HT Palonosetron
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Objectives Palonosetron is a novel 5-hydroxytryptamine 3 (5 HT 3 ) receptor antagonist, which has been shown to be superior to first generation 5 HT 3 receptor antagonists regarding the prevention of acute, delayed and overall chemotherapy-induced nausea and vomiting. First generation 5 HT 3 receptor antagonists may induce electrocardiographic changes of heart rate and repolarization. The acute cardiac effect of palonosteron is unknown. The purpose of this study is to determine acute effects of palonosetron on electrocardiographic (ECG) parameters in cancer patients. Materials and methods The study had a prospective design. Seventy-six cancer patients with normal cardiac function who received palonosetron for prevention of chemotherapy-induced nausea and vomiting were enrolled. Standard 12-lead ECG recordings were performed at baseline and 30 min after palonosetron administration. P wave durations and corrected QT intervals were measured; P wave dispersion (Pd) and QTc dispersion were calculated. Results Median heart rate did not differ among 76 patients enrolled before and after palonosetron administration ( p : 0.6). Systolic and diastolic blood pressures were not significantly different before and after palonosteron ( p values 0.9 and 0.3, respectively). Although median QT min value was higher after palonosetron administration than before palonosetron administration, the difference was not statistically significant ( p : 0.6). Conclusion Palonosetron seems to have no acute arrhythmogenic potential.
ISSN:	0941-4355 1433-7339
DOI:	10.1007/s00520-011-1348-9